| Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention (NCT04555343) | Fraser Health | 2021-03-01 |
| A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (NCT04688931) | UroGen Pharma Ltd. | 2021-02-19 |
| Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) (NCT04574960) | University Health Network, Toronto | 2021-02-08 |
| Evaluation of the PhageTech Virus BioResistor (NCT04756284) | PhageTech, Inc. | 2021-02-08 |
| Impact of Remimazolam on Prognosis After Bladder Cancer Surgery (NCT04532606) | Peking University First Hospital | 2021-02-05 |
| INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (NCT04580485) | Incyte Corporation | 2021-02-03 |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors (NCT04660929) | Carisma Therapeutics Inc | 2021-02-02 |
| Multiparametric Magnetic Resonance Imaging (MRI) to Improve Bladder Cancer Staging and Treatment Decision-making (NCT04533672) | University of Zurich | 2021-02-01 |
| Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC (NCT04543110) | Ottawa Hospital Research Institute | 2021-01-29 |
| Fast Track Protocol After Radical Cystectomy and Urinary Diversion: A Randomised Controlled Trial. (NCT04939194) | Mansoura University | 2021-01-15 |
| Relationship Between Methods of Bladder Tumor Extraction and Local Recurrence Rate (NCT04750590) | I.M. Sechenov First Moscow State Medical University | 2021-01-11 |
| The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical Cystectomy (NCT06358599) | Ankara Etlik City Hospital | 2021-01-07 |
| Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer (NCT04553939) | Henan Cancer Hospital | 2021-01-04 |
| The Application Value of Artificial Intelligence in MRI Precision Diagnosis and Treatment of Bladder Cancer (NCT05096533) | The First Affiliated Hospital with Nanjing Medical University | 2021-01-01 |
| DRG Mutations in Prostate Cancer: a Guiding Light for Enhanced Screening and Personalised Therapy (NCT07265414) | Istituto Clinico Humanitas | 2021-01-01 |
| The Performance of Cancer Risk Genes in the Necessity of Secondary TURBT (NCT05112523) | The First Affiliated Hospital with Nanjing Medical University | 2020-12-20 |
| Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (NCT03740256) | Baylor College of Medicine | 2020-12-14 |
| Safety Analysis and Oncological Outcomes in HoLERT vs TURBT (NCT05833997) | Instituto do Cancer do Estado de São Paulo | 2020-12-10 |
| Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic (NCT04770974) | University of Florence | 2020-12-10 |
| Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients (NCT04604158) | Gillian Gresham | 2020-12-02 |
| Autophagy Bladder Cancer (NCT03254888) | Assiut University | 2020-12-01 |
| Metadherin mRNA Expression in Bladder Cancer (NCT04286672) | Assiut University | 2020-12-01 |
| Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors (NCT04525131) | CicloMed LLC | 2020-11-25 |
| Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (NCT04644068) | AstraZeneca | 2020-11-12 |
| Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS) (NCT04492007) | UNC Lineberger Comprehensive Cancer Center | 2020-11-02 |
| Ileal Conduit Versus Cutaneous Ureterostomy After Radical Cystectomy (NCT04610385) | Assiut University | 2020-11-01 |
| A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets (NCT04601766) | Asieris Pharmaceuticals (AUS) Pty Ltd. | 2020-10-30 |
| Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC (NCT04610671) | H. Lee Moffitt Cancer Center and Research Institute | 2020-10-26 |
| Tempus Priority Study: A Pan-tumor Observational Study (NCT05179824) | Tempus AI | 2020-10-19 |
| The Impact of Manual Versus Mechanical Intestinal Suturing on the Incidence of Postoperative Complications Following Cystectomy With Ileal Conduit (NCT06928220) | Fundacio Puigvert | 2020-10-19 |
| Clinical Evaluation of the miR Sentinel BCa™ Test to Diagnose Bladder Cancer in Hematuria Patients (NCT04155359) | miR Scientific LLC | 2020-10-13 |
| Single-use Cystoscope System for Direct Visualization of the Urethra and Bladder (NCT04190641) | Ambu A/S | 2020-10-08 |
| Prospective Bladder Cancer Infrastructure (ProBCI) (NCT04503577) | Prospective Bladder Cancer Infrastructure Foundation | 2020-10-04 |
| A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors (NCT03914794) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2020-10-02 |
| Nordic Cystectomy Study III - Transfusion (NCT04537221) | Turku University Hospital | 2020-09-30 |
| Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors (NCT04383210) | Elevation Oncology | 2020-09-29 |
| Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer (NCT04738630) | Taizhou Hanzhong biomedical co. LTD | 2020-09-25 |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802) | Ocellaris Pharma, Inc. | 2020-09-24 |
| Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer (NCT03978624) | UNC Lineberger Comprehensive Cancer Center | 2020-09-23 |
| Predicting BCG Response (NCT04564781) | Cedars-Sinai Medical Center | 2020-09-18 |
| En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device (NCT04235764) | National Cancer Institute (NCI) | 2020-09-09 |
| Transurethral Modified En Bloc Resection For Large Bladder Tumours. (NCT04081246) | Chinese University of Hong Kong | 2020-09-07 |
| Propranolol Adjuvant Treatment of Bladder Cancer (NCT04493489) | Central South University | 2020-09-06 |
| Gender-related Characteristics of Bladder Cancer Treatment (NCT04687254) | University of Florence | 2020-09-01 |
| Nordic Cystectomy Study I - Neutrophil-lymphocyte Ratio (NLR) (NCT04523025) | Turku University Hospital | 2020-08-30 |
| Nordic Cystectomy Study II - Albumin (NCT04523038) | Turku University Hospital | 2020-08-30 |
| Efficacy and Safety of Clinical Telesurgery Using Chinese Independently Developed Surgical Robot System (NCT04570176) | The Affiliated Hospital of Qingdao University | 2020-08-27 |
| Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer (NCT06337305) | University of Kansas Medical Center | 2020-08-19 |
| Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer (NCT04386746) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2020-07-29 |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S (NCT04430842) | Quadriga Biosciences, Inc. | 2020-07-20 |
| A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors (NCT04424641) | Genmab | 2020-07-15 |
| Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies (NCT04235777) | National Cancer Institute (NCI) | 2020-07-13 |
| Methadone in Cystectomy Patients (NCT04475029) | University of Aarhus | 2020-07-06 |
| Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy (NCT04442724) | Cedars-Sinai Medical Center | 2020-07-01 |
| Measurements of Sexual Steroids' Concentrations in Prostatic Tissue (NCT04256161) | Hopital Foch | 2020-06-26 |
| Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies (NCT04383938) | Aprea Therapeutics | 2020-06-25 |
| Influence of Opioids on Circulating Tumor Cells in Radical Cystectomy (NCT04358718) | RenJi Hospital | 2020-06-02 |
| Assessment of Urinary Diversions Outcomes Post Radical Cystectomy in Asyut University Urology Hospital (NCT04406168) | Assiut University | 2020-06-01 |
| Quadratus Lumborum Block vs Transversus Abdominis Plane Block in Bladder Cancer Surgeries (NCT04402411) | National Cancer Institute, Egypt | 2020-06-01 |
| TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer (NCT04073160) | Daniel George, MD | 2020-06-01 |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer (NCT04254107) | Seagen Inc. | 2020-05-29 |
| MOdified Urinary Conduit to Lower Strictures After radIcal Cystectomy (NCT04391790) | Jørgen Bjerggaard Jensen | 2020-05-27 |
| Complete Local Response to Neoadjuvant Chemotherapy in Patients With Muscle Invasive Bladder Cancer Evaluated by 15O-H2O PET/MR (NCT04321707) | Jørgen Bjerggaard Jensen | 2020-05-27 |
| Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer (NCT04289779) | Deepak Kilari | 2020-05-21 |
| Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention (NCT03517995) | H. Lee Moffitt Cancer Center and Research Institute | 2020-04-01 |
| Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy (NCT04138628) | Jørgen Bjerggaard Jensen | 2020-03-24 |
| Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder Cancer (NCT04726735) | University Hospital, Bordeaux | 2020-03-16 |
| The Impact of Preoperative Urostomy Education on Patients and Families (NCT04334226) | University of Kansas Medical Center | 2020-03-03 |
| Exercise-based Pre-habilitation in Bladder Cancer Patients Prior to Radical Cystectomy: a Feasibility Study (NCT04223063) | Ross Mason | 2020-03-01 |
| Oncological Outcomes of Different Patterns of Tumor Recurrence at First Evaluation After Bacillus Calmette-Guérin Induction Therapy for Intermediate and High Risk Non Muscle Invasive Bladder Cancer (NCT04319263) | Mansoura University | 2020-03-01 |
| 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy (NCT04018053) | Brigham and Women's Hospital | 2020-02-26 |
| Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer (NCT04282876) | Aarhus University Hospital | 2020-02-19 |
| A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer (NCT04209114) | Bristol-Myers Squibb | 2020-02-05 |
| Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer (NCT04273724) | UNC Lineberger Comprehensive Cancer Center | 2020-01-21 |
| Confocal Laser Endomicroscopy During TransUrethral Resection for Improving BC Diagnosis and Treatment (NCT05273593) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2020-01-06 |
| Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB) (NCT04209192) | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 2020-01-01 |
| Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer (NCT06235853) | Wroclaw Medical University | 2020-01-01 |
| The Global En Bloc Resection of Bladder Tumour Registry (NCT04934540) | Chinese University of Hong Kong | 2020-01-01 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma (NCT04200963) | Ikena Oncology | 2019-12-18 |
| Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors (NCT03023319) | Nagla Abdel Karim | 2019-12-10 |
| Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA (NCT04197414) | Yonsei University | 2019-12-06 |
| Protoves M1® Syrup in Controlling Adverse Event During HIVEC® Instillations (NCT04148677) | Cardarelli Hospital | 2019-12-01 |
| A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8) (NCT04089163) | Tocagen Inc. | 2019-12-01 |
| Prospective Collection of Samples for Urothelial Cancer of Bladder (NCT04167332) | Universitaire Ziekenhuizen KU Leuven | 2019-12-01 |
| Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression (NCT04040725) | Dana-Farber Cancer Institute | 2019-11-27 |
| FITBIT Study on Mobility and Readmissions After Radical Cystectomy (NCT04314778) | University of Pennsylvania | 2019-11-15 |
| Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors (NCT04157985) | Dan Zandberg | 2019-11-15 |
| Bipolar Versus Mono-polar Needlescopic En Bloc TUR-BT (NCT04839029) | Benha University | 2019-11-01 |
| EpiCheck and Short-term Intensive Chemoresection in NMIBC (NCT04162704) | Aarhus University Hospital | 2019-10-28 |
| Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer (NCT03768570) | Canadian Cancer Trials Group | 2019-10-25 |
| Expression of Markers Related to Mitochondrial Functionality in Carcinoma of the Urinary Bladder: Comparative Retrospective Analysis Between Recurrent Tumors ("Non-responders") and Non-recurrent Tumors ("Responders") After Intravesical Treatment With Chemotherapy or Immunotherapy (NCT04256122) | Istituto Clinico Humanitas | 2019-10-22 |
| Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients (NCT04046094) | University of Kansas Medical Center | 2019-10-17 |
| Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy (NCT04068896) | NGM Biopharmaceuticals, Inc | 2019-10-16 |
| Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer (NCT07673016) | Convergent Genomics, Inc. | 2019-10-15 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954) | NeoTX Therapeutics Ltd. | 2019-10-10 |
| Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation (NCT05084586) | Ankara Training and Research Hospital | 2019-10-01 |
| Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) (NCT03980041) | Infinity Pharmaceuticals, Inc. | 2019-09-25 |
| Mood Disorders Bladder Cancer (NCT04036877) | University of Kansas Medical Center | 2019-09-19 |
| Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer (NCT04186013) | Spanish Oncology Genito-Urinary Group | 2019-09-18 |
| Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer (NCT03379909) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2019-09-01 |